摘要
:[目的]对比MVP方案与CAP方案治疗NSCLC的疗效。[方法]74例病人随机分为MVP组和CAP组。MVP组 :MMC6mg/m2,d1,VDS3mg/m2d1,d8,PDD30mg/m2,d1 ～d3 。CAP组 :CTX600mg/m2,d1,ADM(30～40)mg/m2,d1,PDD(20～30)mg/m2,d1～3。两方案皆以21天为一周期 ,使用二个周期后进行评价。[结果]MVP方案与CAP方案有效率分别为40%(16/40)和32 35%(11/34)。两组间疗效没有显著差异(P>0 05)。
To compare the therapeutic effects of MVP and CAP regimen for the treatment of advanced non small cell lung cancer (NSCLC) Seventy four cases were treated with MVP(MMC+VDS+PDD) or CAP(CTX+ADM+PDD) MVP regimen consisted of MMC 6mg/m2,d1,VDS 3mg/m2,d1,d8,PDD 30mg/m2,d1～3 CAP regimen consisted of CTX 600mg/m2,d1,ADM(30～40)mg/m2,d1,PDD(20～30)mg/m2,d1～3 The effect was observed after two cycles at least,with 3 weeks in a cycle Response rate was 40%(16/40) and 32 35%(11/34),respectively for these two regimens No statistical difference was noted in response rate between two groups (P>0 05) [Conclusions]There was no difference in the treatment of NSCLC with MVP regimen and CAP regimen
关键词
非小细胞肺癌
药物疗法
环磷酰胺
阿霉素
non small cell lung cancer
drug therapy
cyclophosphamide
adriamycin
cisplatin
mitomycin
videsine
